

1 **β -Lactamase of *Mycobacterium tuberculosis* shows dynamics in the
2 active site that increase upon inhibitor binding**

3 Running title: Dynamics of BlaC

4

5 Wouter Elings^a, Anamika Gaur^a, Anneloes J. Blok^a, Monika Timmer^a, Hugo van Ingen^{a,b}, Marcellus

6 Ubbink^{a,#}

7 ^a Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands

8 ^b Current address: Bijvoet Center for Biomolecular Research, Utrecht University, Padualaan 8, 3584 CH

9 Utrecht, The Netherlands

10 [#] E-mail: m.ubbink@chem.leidenuniv.nl; phone: +31 71 5274628.

11

12 **ABSTRACT:** The *Mycobacterium tuberculosis* β -lactamase BlaC is a broad-spectrum β -lactamase that can
13 convert a range of β -lactam antibiotics. Enzymes with low specificity are expected to exhibit active site
14 flexibility. To probe the motions in BlaC, we studied the dynamic behavior in solution using NMR
15 spectroscopy. ¹⁵N relaxation experiments show that BlaC is mostly rigid on the pico- to nanosecond
16 time scale. Saturation transfer experiments indicate that also on the high millisecond time scale BlaC is
17 not dynamic. Using relaxation dispersion experiments, clear evidence was obtained for dynamics in the
18 low millisecond range, with an exchange rate of *ca.* 860 s⁻¹. The dynamic amide groups are localized in
19 the active site. Upon formation of an adduct with the inhibitor avibactam, extensive line broadening
20 occurs, indicating an increase in magnitude of the active site dynamics. Furthermore, the rate of the
21 motions increases significantly. Upon reaction with the inhibitor clavulanic acid, similar line broadening
22 is accompanied by duplication of NMR signals, indicative of at least one additional, slower exchange

process ($k_{ex} < 100 \text{ s}^{-1}$), while for this inhibitor also loss of pico- to nanosecond time scale rigidity is observed for some amides in the α -domain. Possible sources of the observed dynamics, such as motions in the omega loop and rearrangements of active site residues, are discussed. The increase in dynamics upon ligand binding argues against a model of inhibitor binding through conformational selection. Rather, the induced dynamics may serve to maximize the likelihood of sampling the optimal conformation for hydrolysis of the bound ligand.

29 KEYWORDS

30 **BlaC, clavulanic acid, avibactam, NMR spectroscopy, inhibition, chemical exchange**

31 INTRODUCTION

32 A central question in chemical biology is how enzymes can have broad specificity. Enzyme catalysis
33 depends on efficient binding of the substrate to the enzyme and on the precise positioning of active site
34 residues to stabilize the transition state. Substrates that are structurally diverse may require different
35 active site conformations to efficiently bind the substrates and stabilize their respective transition
36 states.(1–10) Consequently, a trade-off between active site rigidity for precise positioning of amino acid
37 sidechains and flexibility for adaptation to various substrates will exist, requiring motions of parts of the
38 enzyme. Protein motions can occur on a broad range of time scales. It has been hypothesized that
39 enzymes that combine high catalytic efficiency with broad specificity, do so by combining high rigidity
40 on short time scales with flexibility on longer time scales.(11) The dynamic behavior of Ambler class A
41 β -lactamases TEM-1 and PSE-4 is in line with this idea (e.g. (11–16)). A combination of NMR
42 backbone dynamics studies and molecular dynamics (MD) simulations has revealed that these proteins
43 are extraordinarily rigid on the pico-nanosecond timescale, and display microsecond to millisecond
44 timescale motions in the vicinity of the active site, in particular in the Ω -loop that encloses it on one side
45 (Figure 1). Dynamics experiments on proposed β -lactamase ancestors(17–19) and chimera proteins(20,

21) suggested that this pattern of dynamics is a conserved feature. However, significant dynamic
46 differences were found for individual residues, emphasizing the importance of comparing various β -
47 lactamases.(15, 22) The leading structural model to explain the active site dynamics is a slow motion of
48 the Ω -loop into and out of the active site. This loop contains residue Glu166, which acts as a general
49 base for deacylation, activating a conserved water molecule for nucleophilic attack of the Ser70-bound
50 carbonyl, which leads to hydrolysis of the bond between enzyme and adduct. Glu166 is also thought to
51 play a similar role in acylation, although Lys73 has alternatively been proposed as general base for this
52 step.(23, 24) Furthermore, other residues in the Ω -loop, such as Asn170, also contribute favorable
53 enzyme-substrate interactions. These interactions may require slightly different enzyme conformations
54 with various substrates. If active site flexibility is indeed required for adaptation to various substrates, it
55 can be hypothesized that ligand binding will lock the active site in one conformation and thus freeze out
56 the dynamics. NMR dynamics studies on β -lactamase / ligand complexes have not been reported to date,
57 although the potential relevance of insight into the bound state dynamics has been recognized for
58 years.(15) The absence of such data may be due to technical difficulties, as the typical length of NMR
59 dynamics experiments is several days, restricting such studies to extremely stable complexes. Clearly,
60 monitoring the dynamics during normal catalysis of substrates in this way is not feasible. However, β -
61 lactamases do form stable covalent complexes with inhibitors. Inhibition of β -lactamases has clinical
62 application(25–27) and is gaining in relevance with the increased prevalence of antibiotic
63 resistance.(28–30) In addition to this inherent interest in β -lactamase inhibition, inhibitor-bound β -
64 lactamases may also serve as a mimic of the covalent β -lactamase substrate complex during catalysis.
65 We recently characterized the timescale of interaction between the β -lactamase of *Mycobacterium*
66 *tuberculosis*, BlaC (Figure 1), and the inhibitor clavulanic acid in different buffers.(31) The high
67 stability of the complex in MES buffer opens up a window for NMR dynamics measurements. Also the
68 effects of the inhibitor avibactam, which binds reversibly rather than being degraded,(32) can be
69 measured using these techniques.

71 Here, we present the dynamic properties of BlaC and the first characterization of β -lactamase /
72 inhibitor complex dynamics. The dynamic behavior of resting state BlaC in solution is very similar to
73 that of other class A β -lactamases and the rate of the active site exchange process is *ca.* 860 s⁻¹ at 298 K.
74 The high rigidity, which is a hallmark of β -lactamases, is locally lost upon inhibition by clavulanic acid.
75 Furthermore, upon binding to either clavulanic acid or avibactam, the effects of chemical exchange in
76 the active site become more extensive, clearly showing that inhibitor binding does not lock the active
77 site in one conformation.

78 **MATERIALS AND METHODS**

79 **Materials.**

80 Pure BlaC without signal peptide and purification tag (sequence detailed in Figure S1) was obtained as
81 described previously.(31) The Ambler standard β -lactamase numbering scheme (Figure S1) is used
82 throughout this text.(33) Clavulanic acid from manufacturer Matrix Scientific was used, concentrations
83 were determined using the previously determined extinction coefficient at 256 nm of 20.0 (0.1) mM⁻¹
84 cm⁻¹.(31) Avibactam was used from manufacturer MedChem Express, concentration was determined
85 using 1D ¹H quantitative NMR with TSP as a known standard.

86 **Methods.**

87 Unless mentioned otherwise, all experiments were performed on samples containing 0.38 mM ¹⁵N
88 enriched BlaC in 94 mM MES/NaOH pH 6.4 and 6 % D₂O, at 298 K. Measurements of inhibitor-bound
89 BlaC were performed on samples obtained by mixing BlaC with the inhibitor in the same buffer, to
90 concentrations after mixing of 0.38 mM BlaC and either 100 mM clavulanic acid or 2 mM avibactam,
91 unless mentioned otherwise. NMR spectra were recorded on a Bruker AVIII HD 850 MHz (20 T) or
92 Bruker AVIII 600 MHz (14 T) spectrometer equipped with a TCI cryoprobe or a TXI probe,
93 respectively. ¹H, ¹⁵N transverse relaxation optimized heteronuclear single quantum coherence (TROSY-
94 HSQC)(34, 35) spectra were recorded and assigned using HNCA spectra on samples containing 0.7, 0.4
95 or 0.3 mM ¹⁵N, ¹³C enriched BlaC without inhibitor, with 186 mM clavulanic acid or with 2 mM

96 avibactam, respectively, in the same buffer. These spectra were recorded using standard Bruker pulse
97 program ‘trhncaetgp3d’, processed with Topspin 3.2 (Bruker Biospin) and analyzed using CCPNmr
98 Analysis.(36) Assignment was performed by comparison of the TROSY-HSQC and HNCa spectra with
99 those of the previously assigned BlaC with a 6×His purification tag (Biological Magnetic Resonance
100 Bank (BMRB) ID 27067).(31) Nuclear Overhauser effect (*NOE*) measurements were performed using
101 standard Bruker pulse program ‘hsqcnoef3gpsi’, with a ¹H saturation delay of 4 s. ¹⁵N longitudinal
102 relaxation time (*T₁*) measurements were performed using standard Bruker pulse program
103 ‘hsqct1etf3gpsitc3d’, with a recycle delay between experiments of 6 s and variable delays of 0.12, 0.17,
104 0.24 (2x), 0.33, 0.46, 0.65, 0.91, 1.28 (2x), 1.78 and 2.50 s. ¹⁵N transverse relaxation time (*T₂*)
105 measurements were performed using standard Bruker pulse program ‘hsqct2etf3gpsitc3d’, with a
106 recycle delay between experiments of 4 s and 500 Hz CPMG refocusing strength during variable *T₂*-
107 delays of *ca.* 0, 17, 34 (2x), 51, 68, 85, 102, 119 (2x), 136 and 153 ms. All relaxation experiments were
108 acquired in an interleaved manner. *T₁* and *T₂* data were processed with Topspin 3.2 and resulting peak
109 heights were fitted to exponential decay curves using Dynamics Center 2.5 (Bruker BioSpin). *NOE* data
110 were processed and analyzed with the same software.

111 Lipari-Szabo analysis was performed with Dynamics Center 2.5. Only residues for which the *NOE* >
112 0.75 and the *T₁* and *T₂* values were each within one standard deviation of their respective means were
113 used to fit the diffusion tensor. The diffusion was found to be anisotropic, with average rotational
114 correlation time $\tau_c = I / (2 \times (D_{xx} + D_{yy} + D_{zz}))$ (37) in line with a prediction from subunit A of crystal
115 structure 5NJ2, after deletion of the histidine tag and linker, using HydroNMR(38). Least-squares fitting
116 of the reduced spectral density function, $j(\omega)$, to the relaxation parameters was performed with 1000
117 iterations with random starting parameters, using an NH bond length of 1.02 Å and an average chemical
118 shift anisotropy of -160 ppm. To avoid overfitting of relaxation parameters with small errors, Lipari-
119 Szabo analyses were performed with user-defined errors of 10 % (*T₁*) and 5 % (*T₂* and *NOE*) of the
120 respective values. Relaxation data from each residue were fitted with the five standard models for
121 internal motions, using anisotropic overall motion.(39, 40) In Model 1, the order parameter S^2 is fitted

for each residue, while the correlation times τ_j are calculated from components and orientation of the diffusion tensor, which is a global parameter. In Model 2, a local correlation time τ_e for fast motion is additionally fitted individually for each residue. Model 3 is the same as Model 1, except that an R_{ex} term is added to the R_2 in the calculation of the reduced spectral densities. Likewise, Model 4 is the same as Model 2 with the addition of an R_{ex} term. In Model 5, an extra modelling parameter S_f^2 is included for very fast local motion. The best model was selected based on the lowest *AIC* value, which is the sum of the χ^2 of the fit and the number of fitted parameters $\times 2$. The selected model for each residue is reported with the relaxation data at BMRB (*vide supra*).

CPMG relaxation dispersion measurements were performed on 1.0, 0.8 or 0.4 mM ^{15}N enriched BlaC samples, for free protein at 20 T, at 14 T or with 100 mM inhibitor at 20 T, respectively. The TROSY CPMG pulse program as detailed by Vallurupalli *et al.*(41) was used, with two blocks of 1 (2x), 2, 3 (2x), 4, 6, 8, 10 (2x), 14, 18, 22, 28, 34 and 40 ^{15}N 180° pulses in 40 ms relaxation time, respectively. The length of the CPMG refocusing pulse was 84 μs and the carrier was set to the center of the spectrum at 119 ppm. Data were acquired in interleaved manner with a recycle delay of 2 s. Data were processed with NMRPipe(42) and resulting resonances were fitted to a glore line shape using FuDa.(43) Effective transverse relaxation rates $R_{2,\text{eff}}$ were calculated from the fitted peak heights using $R_{2,\text{eff}}(\nu_{CPMG}) = -\ln(I(\nu_{CPMG}) / I_0) / T_{ex}$. In the relaxation dispersion data of BlaC bound to clavulanic acid, 29 of the 208 fitted profiles showed variations that were much bigger than the experimental noise. This variation is likely due to technical imperfections, so these data points were excluded from further analysis. An exclusion cut-off of 10 s^{-1} total increase in $R_{2,\text{eff}}$ between subsequent pulse frequencies was used. Chemical exchange rates were determined with a grouped fit with the software CATIA,(44) using a minimum $R_{2,\text{eff}}$ standard deviation of 0.8 s^{-1} to avoid over-fitting.

Chemical exchange saturation transfer (CEST) measurements were performed on 0.8 mM ^{15}N BlaC samples, using the standard Bruker ‘hsqc_cest_etf3gpsitc3d’ pulse program, with 2.5 s recycle delay and 0.8 s B_1 irradiation at 8 and 25 Hz at frequencies in the ^{15}N range 100.5:0.5:130 ppm.

147 Titration of BlaC with avibactam was performed by adding a solution of 6 mM avibactam in 94 mM
148 MES/NaOH pH 6.4 and 6 % D₂O to a sample of 0.27 mM ¹⁵N enriched BlaC in the same buffer, to
149 concentrations of 0, 0.02, 0.07, 0.1, 0.2, 0.3, 0.4, 0.6, 0.7 and 0.9 mM avibactam. The final protein
150 concentration was 0.23 mM. Affinity and off-rate were determined by fitting the peak shapes of Cys69,
151 Arg161, Leu162, Glu168, Tyr241 and Ala274 over the course of the titration to a two-state binding
152 model in TITAN.(45) The resulting standard deviations of the fitted K_D and k_{off} were unrealistically
153 small, even after bootstrapping with 100 replicas, so the values are reported as an estimated confidence
154 interval based on systematic variation of the parameters (Figure S2).

155 Figures containing the protein structure were created using the PyMOL Molecular Graphics System,
156 Version 2.2 Schrödinger, LLC.

157 **Data availability.**

158 NMR chemical shift assignments and relaxation data have been submitted to the BMRB and can be
159 accessed under BMRB IDs [27888](#) (free state), [27890](#) (clavulanic acid adduct-bound state) and [27929](#)
160 (avibactam-bound state).

161 **RESULTS**

162 **Resting state BlaC.**

163 The ¹H, ¹⁵N correlation spectra of BlaC are well dispersed (Figure S3). The backbone amide
164 assignment of resting state BlaC without tag was derived from the previously published assignment of
165 the tagged protein(31) via comparison with an HNCa spectrum. In this way, 98% of the resonances of
166 the BlaC backbone H–N moieties could be assigned. As with the tagged protein, the four residues at
167 hydrogen-bonding distance from the active site phosphate were the only nonproline, nonterminal
168 residues for which backbone resonances could not be found. The four missing resonances, as well as the
169 lower peak intensities of the surrounding amides (Figure 2a, black squares), suggest that an
170 intermediate-to-fast exchange process may be present in the active site.

To characterize the dynamics processes, the ^{15}N longitudinal relaxation time (T_1), ^{15}N transverse relaxation time (T_2) and the $^{15}\text{N}-\{\text{H}\}$ nuclear Overhauser effect (NOE) of the BlaC backbone amides were measured at two magnetic fields, 14 T and 20 T (Figures S4 and S5). The obtained NOE ratios show lower values for loop and surface regions of the protein as well as an unexpectedly low ratio for Val80 (Figure S4), but overall BlaC is clearly a rigid protein on the pico-nanosecond time scale. Lipari-Szabo model-free analysis of the two-field T_1 , T_2 and NOE data was performed using an anisotropic diffusion tensor, yielding an average rotational correlation time of 13.81 ± 0.04 ns. This is in agreement with an estimate using HydroNMR(38) and crystal structure 5NJ2(31) (14.5 ns). Fitting of the spectral densities resulted in an average order parameter over 0.9 and yielded very few dynamic regions, confirming that BlaC is rigid on the short time scales (Figure S6). Most amides were best fitted with anisotropic models 1-4 (see Materials and Methods). Only for Val80, model 5, including an extra local order parameter S_f^2 for very fast motion, was used to fit the data. The resulting order parameters are $S_f^2 = 0.79 \pm 0.03$ and $S^2 = 0.57 \pm 0.02$, the latter of which is the lowest order parameter in the protein. The other regions that exhibit some flexibility correspond with elements that are expected to be flexible based on the structure, such as the loop between β -strands 1 and 2 and that between α -helices 7 and 8.

Several residues could not be modelled without the inclusion of a chemical exchange parameter, so the possibility of exchange on the millisecond time scale was examined using CPMG relaxation dispersion measurements at magnetic field strengths of 14 T and 20 T. Dispersion of relaxation rates over the CPMG pulse frequency, indicating millisecond chemical exchange, was observed centered clearly around the active site (Figure 3 (a) and (c), spheres in orange).

Eight active site residues that showed similar dispersion profiles at both magnetic field strengths were used in a group fit (Figures 4 and S7) yielding a chemical exchange rate of $(8.6 \pm 0.6) \times 10^2$ s $^{-1}$. This exchange rate agrees with the $(8.5 \pm 2.1) \times 10^2$ s $^{-1}$ that was found for TEM-1 with single-field relaxation dispersion.(21) The excited state population and chemical shift differences could not be determined with any accuracy.

196 To investigate the possibility of even slower dynamic processes, chemical exchange saturation transfer
197 (CEST) in resting state BlaC was also measured. Experiments with saturation fields of 25 Hz and 8 Hz
198 and at temperatures of 298 K and 288 K all failed to reveal chemical exchange for any of the residues,
199 suggesting that no significant dynamics in the CEST time scale of 20 - 200 s⁻¹ are present. An example
200 profile is provided in Figure S8.

201

202 **Inhibitor-bound BlaC.**

203 The effect of BlaC inhibition on its dynamic behavior was studied by performing NMR experiments
204 on 0.38 mM BlaC with 2 mM avibactam or 100 mM clavulanic acid. Avibactam is not hydrolyzed by
205 BlaC, as was observed by others(32, 46) and also in our experiments (not shown). Clavulanate has a
206 ~1.2 h turnover time under these conditions,(31) so this large excess of clavulanic acid allowed the
207 recording of multidimensional NMR experiments on the BlaC/inhibitor complex. This turnover rate is
208 much too slow to affect the employed NMR dynamics experiments. Furthermore, the rate is much
209 slower than the other catalytic steps, so the adduct accumulates to a fraction close to 100%. Previously,
210 this major species was shown by mass spectrometry to be a 70 Da covalent adduct.(31) Thus, the NMR
211 dynamics measurements report on conformational dynamics of this major species. The ¹H-¹⁵N TROSY-
212 HSQC spectra of backbone amides of BlaC bound to each inhibitor were assigned by comparison to the
213 spectra of resting state BlaC, with additional help of HNCA spectra of ¹⁵N, ¹³C labelled BlaC-inhibitor
214 samples to confirm the assignments.

215

216 **Avibactam.**

217 Avibactam was titrated into a BlaC sample and ¹H-¹⁵N TROSY-HSQCs were recorded at various
218 avibactam concentrations, showing chemical shift perturbations of the BlaC backbone amide resonances
219 in the slow exchange regime. Lineshapes for the resonances of six amides were fitted with a two-state
220 binding model using TITAN software,(45) yielding upper limits for the apparent K_D and k_{off} of 10 μM

and 10 s^{-1} , respectively (Figure S2). This apparent k_{off} is in line with the $1 \times 10^{-2} \text{ s}^{-1}$ found by Soroka *et al.*,⁽³²⁾ while the apparent K_D indicates that the low efficacy of BlaC inhibition by avibactam is caused by the very slow on-rate rather than by low affinity. Interestingly, several peaks that are visible in the spectrum of resting state BlaC broaden beyond detection upon binding with avibactam (Figure 2). These peaks correspond to amides around the binding site, indicating that inhibitor binding induces enhanced chemical exchange broadening in the active site. T_1 , T_2 and NOE experiments performed at 20 T (Figures S9 and S10) show little change in dynamic behavior relative to the resting state, other than decreased transverse relaxation times around the loop containing Ile105. Like the exchange broadening, this hints at induction of a slow or intermediate exchange process. The unexpectedly high transverse relaxation time and low NOE for Val80 were not found in the avibactam-bound state.

CPMG relaxation dispersion measurements at 20 T showed an increased magnitude of the exchange relaxation in the loops of the α domain, around the residues whose resonances broadened beyond detection (Figure 3). The exchange profiles of the individual residues over the pulse frequency are visibly different from those in the free state (Figures 4 and S11), indicating a significantly faster exchange process than the 860 s^{-1} that was found for resting state. A single field global fit of the exchange profiles of 19 backbone amides (Figure S11) yielded an estimate of the active site exchange rate in avibactam-bound state of $(3.4 \pm 0.2) \times 10^3 \text{ s}^{-1}$. The exchange between free and avibactam-bound BlaC is very slow ($<<100 \text{ s}^{-1}$), so the chemical exchange process measured here occurs in the bound state. The enhanced exchange effects are observed around the binding site, particularly in the loops containing Ser130 and Ile105.

241

242 **Clavulanic acid.**

Upon binding with clavulanic acid, like with avibactam, the resonances of several amides around the binding site broaden beyond detection (Figure 2). Moreover, in the clavulanic acid adduct-bound state, at least 21 resonances were found to split into two or more distinct peaks of similar intensity. These

peaks belong to amides around the active site and in the α -domain (Figure 5, magenta and orange spheres). Furthermore, the clavulanic acid adduct-bound state of BlaC is less stable over time than the free and avibactam-bound states. Over the course of days, a gradual appearance of broad background signal in the center of the spectrum was observed, suggesting the formation of molten globule.

The T_1 , T_2 and NOE of clavulanate-bound BlaC were measured at 20 T (Figures S9 and S10). Average relaxation times (T_1 and T_2 , respectively) were found to have shifted from 1.7 s and 45 ms for resting state BlaC to 1.8 s and 40 ms for the adduct, which may be caused by an increase in sample viscosity due to the addition of 100 mM clavulanic acid. Strikingly higher transverse relaxation times were found for several residues in and near loops and terminal regions, as well as for six residues involved in the hydrophobic packing interface between helices 2 and 7 in the α subunit. Moreover, for these residues, the NOE is lower than in resting state BlaC. These observations indicate a severe local decrease of internal rigidity upon clavulanic acid inhibition, particularly in loop regions and on the interface between helices 2 and 7.

CPMG relaxation dispersion measurements at 20 T were also performed on clavulanate-bound BlaC. However, most of the resonances that show exchange broadening in the resting state protein were broadened beyond detection in the clavulanate-bound spectra. Moreover, due to the splitting of peaks and the gradual appearance of molten globule-like background signal over time, accurate line shape fitting of the resonances proved impossible in many cases. Residues Glu168 and Asp273 were found to have dispersion profiles with shapes similar to the active site exchange of the resting state protein (e.g. Figure 4, panel (b)). Slight elevations in the R_{ex} are observed around the loop containing Ile105, near the base of the Ω -loop and for residue Asp273, but overall the profile of exchange relaxation over all residues, keeping in mind the larger error and the missing data, looks rather similar to that of resting state BlaC (Figure 3). Thus, it seems that the resting state BlaC dynamics are still present upon formation of the clavulanic acid adduct and at the same time additional states are being populated, causing line broadening and peak splitting.

271 DISCUSSION

272 We show that resting state BlaC is mostly rigid on the pico- to nanosecond time scale, similar to the
273 behavior of the other class A β -lactamases for which NMR dynamics studies have been performed,
274 TEM-1(11, 13, 14) and PSE-4.(15) Only Val80 was found to exhibit fast motion, as modelled from the
275 low NOE ratios and elevated T_2 relaxation times for its backbone amide. This is surprising, as this amide
276 is located in the long α -helix 2 and the Val80 side chain does not face the outside of the protein but
277 rather the interface between helices 2 and 7.

278 The BlaC active site exhibits flexibility on the millisecond time scale, as observed by both CPMG
279 relaxation dispersion studies and the broadening beyond detection of several important active site
280 residues (Ser70, Ser130, Thr235 and Thr237). This behavior is also similar to that of other class A β -
281 lactamases,(11–20) and the localization of this chemical exchange in the active site suggests that the
282 dynamics may play a role in catalysis. This can only be the case if the dynamics are as fast as or faster
283 than the maximum catalytic turnover rate of the enzyme. The observed exchange rate of $(8.6 \pm 0.6) \times$
284 10^2 s^{-1} -obtained under the assumption of a two-state exchange model- is faster than the fastest k_{cat} that
285 was reported for BlaC, $111 \pm 4 \text{ s}^{-1}$ for nitrocefin hydrolysis,(47) which implies that enzyme dynamics
286 may be relevant for catalysis. On the basis of the Bloch-McConnell equations for chemical exchange, it
287 can be shown that at an exchange rate of 860 s^{-1} , the population of the minor state must be sizeable (>15
288 %) for the resonances of Ser70, Ser130, Thr235 and Thr237 to broaden beyond detection. The chemical
289 shift difference between the major and minor state must be larger than 0.1 ppm for ^1H and/or 1 ppm for
290 ^{15}N at 20 T. The link between these four residues is that in every BlaC crystal structure published to
291 date, their respective sidechains each contribute to the hydrogen bonding with either the carboxyl group
292 of a ligand or a phosphate or acetate ion from the buffer. However, upon titration with phosphate, the
293 resonances do not appear,(31) meaning that the binding and dissociation of phosphate cannot explain the
294 chemical exchange broadening of these peaks.

295 We also report the first dynamics study of a class A β -lactamase dynamics upon inhibitor binding. On
296 the pico-nanosecond time scale the reaction with avibactam stabilizes the Val80 amide, while that with
297 clavulanic acid leads to fast motions for various residues, notably including several that are involved in
298 the hydrophobic packing interface between helices 2 and 7, similar to what was observed for Val80 in
299 resting state BlaC. This result resembles the observation by Stivers *et al.* that several residues of 4-
300 oxalocrotonate tautomerase show a decrease in the order parameter upon inhibitor binding.(48) The
301 authors suggest that the increased flexibility of these residues serves as an entropic contribution to the
302 overall free energy change upon binding, which may well be the same for BlaC. An increase in fast
303 dynamics of backbone amides generally indicates increased flexibility of the peptide bond. Many of the
304 amides for which we observe this phenomenon are on the interface of helices 2 and 7. An increase of
305 backbone flexibility implies reduced stability of the hydrophobic core in that region of the α -domain.

306 On the millisecond time scale, binding of BlaC to either avibactam or clavulanic acid leads to
307 increased effects of dynamics. In the avibactam-bound state, we observe broadening beyond detection of
308 some peaks and relaxation dispersion of others. All affected amides surround the active site. For the
309 broadening beyond detection to be caused by the $\sim 3400\text{ s}^{-1}$ exchange process identified using CPMG
310 experiments, would require chemical shift differences between the two states that are larger than *ca.* 0.3
311 ppm for ^1H and/or 3 ppm for ^{15}N at 20 T. Alternatively, it is possible that multiple exchange processes
312 take place in the same region of the protein. In any case, the relaxation dispersion results suggest that
313 avibactam binding speeds up the active site exchange process in BlaC significantly.

314 Inhibition of BlaC with clavulanic acid was likewise accompanied by a broadening of many
315 resonances, in and around the active site of BlaC. These experiments were performed in the presence of
316 a high initial concentration of clavulanic acid, so it cannot be excluded entirely that non-covalent
317 binding of an additional clavulanic acid molecule to the BlaC adduct could cause line broadening.
318 However, an earlier study on such binding to a catalytically inactive mutant of BlaC (S70A) showed

319 that, if binding occurs at all, the affinity must be very low indeed and line broadening in the BlaC NMR
320 spectrum was not observed.(49) Therefore, we attribute the increased dynamics to the adduct formation.

321 The chemical environment of all the catalytic residues as well as residues in all the nearby regions
322 appears to be affected by the motions. Interestingly, β -lactam binding was previously reported to also
323 cause increased millisecond dynamics in the active site of an L,D transpeptidase(50) as well as in that of
324 a signal transducer β -lactam sensing domain,(51) suggesting that this behavior might be conserved
325 across a wide range of β -lactam binding proteins.

326 The question arises how these relatively small adducts, especially the clavulanic acid adduct, which is
327 a mere 70 Da (5 heavy atoms), can have such a major impact on such a broad region of the protein.
328 Sagar *et al.*(52) reported small angle X-ray scattering (SAXS) data yielding an unexpectedly large
329 solvation radius for free BlaC in solution, while BlaC bound to clavulanic acid was found to have a
330 solvation radius closer to that which is expected based on the crystal structure. The authors proposed
331 that free BlaC in solution adopts an ‘open’ conformation, whereas inhibitor binding locks BlaC in the
332 ‘closed’ conformation that is observed in all crystal structures so far. If resting state BlaC were indeed to
333 adapt an open conformation in solution, it would likely exhibit a larger rotational correlation time and
334 thus higher transverse and lower longitudinal relaxation times than in the canonical closed
335 conformation. The correlation time measured for the free BlaC on the basis of the relaxation data
336 matched the one calculated from the crystal structure. Binding avibactam did not change the relaxation
337 times much and the sample with clavulanic acid bound even yielded relaxation times indicating an
338 increase of the correlation time. However, the latter was likely caused by an increase in sample viscosity
339 due to the high concentration of the inhibitor. Summarizing, our data provide no evidence for an open
340 state of resting state BlaC. For related β -lactamases, it has been suggested (e.g. (11, 15, 16)) that the
341 process underlying the chemical exchange effects is movement of the tip of the omega-loop into and out
342 of the active site. Such movement could facilitate the flow of solvent and substrate, and aid in
343 positioning of the substrate in the active orientation. If so, the motion would likely affect amides in all

344 regions that are in contact with the tip of the Ω -loop, such as helix 7 and the loops containing Ser130
345 and Ile105. This model thus fits well with our data.

346 To gain more insight into what the various states may look like structurally, we compared bound and
347 unbound β -lactamase crystal structures. Most structures show little variation between bound and
348 unbound forms. In structure 6H2H(49) of BlaC bound to avibactam, however, the Ω -loop was observed
349 in a slightly ‘open’ conformation, with the C_α atoms of Asn170 and Arg171 positioned ~ 2 Å further
350 away from the active site than its canonical position, providing further support for the model of Ω -loop
351 movement (Figure 6). Our data suggest the presence of multiple dynamic processes in the bound state.
352 Recently, Olmos *et al.*(53) reported an XFEL study with snapshots at 30, 100, 500 and 2000 ms of the
353 catalytic reaction of ceftriaxone hydrolysis by BlaC. The structures obtained during the reaction show
354 almost no structural variation compared to that of BlaC in the resting state. The only active site residues
355 of which the orientation varies between the structures are Lys73 and Ser130. The Lys73 orientations are
356 similar to those reported by Vandavasi *et al.* for class A β -lactamase Toho-1,(24) except that the non-
357 canonical conformation is oriented towards Ser130, whereas in BlaC it is oriented towards Glu166. One
358 of these conformations allows an extra water molecule to penetrate deep into the active site, between
359 helix 2 (Lys73) and helix 7 (Met135, which is an alanine in BlaC), suggesting a defect of the
360 hydrophobic core such as we observe upon clavulanic acid binding in BlaC. The occupancies of the
361 observed states, 41 and 59 %, respectively, also match the relative occupancies of the doubled peaks of
362 42 ± 3 % that we observe in our clavulanic acid adduct-bound state spectra. An increasing body of
363 evidence suggests that Lys73 can act as a general base for catalysis (e.g. (24, 54–57)). Langan *et al.*
364 even found that in Toho-1 β -lactamase, Lys73 and several other active site residues alter their
365 conformations in reaction to substrate binding.(58) It therefore seems possible that the chemical
366 exchange we observe upon clavulanic acid binding is related to the interconversion of Lys73 between
367 different conformations (Figure 7). As has been suggested before (e.g. (56, 58, 59)), the Lys73 sidechain
368 may need to be in one conformation for efficient substrate binding and another for efficient product
369 release. Thus, it seems possible that the two conformations observed in crystal structures of Toho-1(24,

370 57–60) and BlaC,(53) are the cause of the two forms that we observe in the NMR spectra of the BlaC-
371 clavulanic acid adduct. In this way the effects of addition of the small adduct to Ser70 can be
372 transmitted further into and around the active site.

373 In conclusion, we show that BlaC is highly rigid on the pico-nanosecond time scale, but exhibits
374 flexibility on the millisecond time scale in and around the active site, with an exchange rate of *ca.* 860 s⁻
375 ¹. The dynamic behavior of free BlaC is very similar to that of the other class A β-lactamases for which
376 dynamics studies were performed and therefore appears to be conserved amongst class A β-lactamases.
377 We also show that upon inhibition with clavulanic acid, pico-nanosecond stability of the hydrophobic
378 core in the α-domain is disturbed. Moreover, upon binding of either clavulanic acid or avibactam, the
379 prevalence of millisecond dynamics around the active site increases dramatically. In this work we
380 studied the dynamics in BlaC-inhibitor complexes, so the question remains what effect this phenomenon
381 has on the time scale of substrate catalysis. We hypothesized that active site flexibility of β-lactamases
382 represents exchange between respective binding modes for the various substrates. The observation that
383 inhibitor binding does not lock the active site in one conformation but rather increases the dynamics,
384 argues against a model of inhibitor binding through conformational selection. Rather, the induced
385 dynamics may serve to maximize the likelihood of sampling the precise conformation that lowers the
386 hydrolysis transition state energy barrier for this substrate the most.

387

388 **ASSOCIATED CONTENT**

389 **Supporting information**

390 Supplemental material for this article may be found in the enclosed document.

391 **AUTHOR INFORMATION**

392 **Corresponding author.**

393 [#] E-mail: m.ubbink@chem.leidenuniv.nl; phone: +31 71 5274628.

394 **ORCID**

395 Wouter Elings: 0000-0003-0304-2874

396 Hugo van Ingen: 0000-0002-0808-3811

397 Marcellus Ubbink: 0000-0002-2615-6914

398 **Funding**

399 This study was supported by internal funding and by grant number 723.013.010 from the Netherlands
400 Organization for Scientific Research (NWO).

401 **Notes**

402 The authors declare no competing financial interest.

403 **ACKNOWLEDGEMENTS**

404 We would like to thank dr. Karthick Sai Sankar Gupta and Alfons Lefeber for their assistance with the
405 NMR spectrometers and prof. Lewis Kay for providing the TROSY-CPMG pulse sequence.

406 **REFERENCES**

- 407 1. Greives N, Zhou H-X. 2014. Both protein dynamics and ligand concentration can shift the
408 binding mechanism between conformational selection and induced fit. Proc Natl Acad Sci U S A
409 111:10197–10202.
- 410 2. Vogt AD, Di Cera E. 2012. Conformational selection or induced fit? A critical appraisal of the
411 kinetic mechanism. Biochemistry 51:5894–5902.
- 412 3. Du X, Li Y, Xia Y-L, Ai S-M, Liang J, Sang P, Ji X-L, Liu S-Q. 2016. Insights into Protein-
413 Ligand Interactions: Mechanisms, Models, and Methods. Int J Mol Sci 17.
- 414 4. Yon JM, Perahia D, Ghélis C. 1998. Conformational dynamics and enzyme activity. Biochimie
415 80:33–42.
- 416 5. Wand AJ. 2001. Dynamic activation of protein function: A view emerging from NMR
417 spectroscopy. Nat Struct Biol 8:926–931.

- Accepted Manuscript Posted Online
Antimicrobial Agents and Chemotherapy
AAC
- 418 6. Kay LE. 2005. NMR studies of protein structure and dynamics. *J Magn Reson* 173:193–207.
- 419 7. Bhabha G, Lee J, Ekiert DC, Gam J, Wilson IA, Dyson HJ, Benkovic SJ, Wright PE. 2011. A
420 Dynamic Knockout Reveals That Conformational Fluctuations Influence the Chemical Step of
421 Enzyme Catalysis. *Science* (80-) 332:234–238.
- 422 8. Kohen A. 2015. Role of Dynamics in Enzyme Catalysis: Substantial versus Semantic
423 Controversies. *Acc Chem Res* 48:466–473.
- 424 9. Kovermann M, Rogné P, Wolf-Watz M. 2016. Protein dynamics and function from solution state
425 NMR spectroscopy. *Q Rev Biophys.*
- 426 10. Petrović D, Risso VA, Kamerlin SCL, Sanchez-Ruiz JM. 2018. Conformational dynamics and
427 enzyme evolution. *J R Soc Interface* 15.
- 428 11. Fisette O, Morin S, Savard P-Y, Lagüe P, Gagné SM. 2010. TEM-1 backbone dynamics-insights
429 from combined molecular dynamics and nuclear magnetic resonance. *Biophys J* 98:637–645.
- 430 12. Roccatano D, Sbardella G, Aschi M, Amicosante G, Bossa C, Nola A Di, Mazza F. 2005.
431 Dynamical Aspects of TEM-1 β-Lactamase Probed by Molecular Dynamics. *J Comput Aided
432 Mol Des* 19:329–340.
- 433 13. Savard P-Y, Gagné SM. 2006. Backbone dynamics of TEM-1 determined by NMR: Evidence for
434 a highly ordered protein. *Biochemistry* 45:11414–11424.
- 435 14. Doucet N, Savard P-Y, Pelletier JN, Gagné SM. 2007. NMR investigation of Tyr105 mutants in
436 TEM-1 beta-lactamase: dynamics are correlated with function. *J Biol Chem* 282:21448–21459.
- 437 15. Morin S, Gagné SM. 2009. NMR Dynamics of PSE-4 β-Lactamase: An Interplay of ps-ns Order
438 and μs-ms Motions in the Active Site. *Biophys J* 96:4681–4691.
- 439 16. Fisette O, Gagné S, Lagüe P. 2012. Molecular Dynamics of Class A β-lactamases—Effects of
440 Substrate Binding. *Biophys J* 103:1790–1801.
- 441 17. Risso VA, Gavira JA, Mejia-Carmona DF, Gaucher EA, Sanchez-Ruiz JM. 2013. Hyperstability
442 and Substrate Promiscuity in Laboratory Resurrections of Precambrian β-Lactamases. *J Am
443 Chem Soc* 135:2899–2902.

- 444 18. Zou T, Risso VA, Gavira JA, Sanchez-Ruiz JM, Ozkan SB. 2015. Evolution of Conformational
445 Dynamics Determines the Conversion of a Promiscuous Generalist into a Specialist Enzyme. *Mol*
446 *Biol Evol* 32:132–143.
- 447 19. Risso VA, Martinez-Rodriguez S, Candel AM, Krüger DM, Pantoja-Uceda D, Ortega-Muñoz M,
448 Santoyo-Gonzalez F, Gaucher EA, Kamerlin SCL, Bruix M, Gavira JA, Sanchez-Ruiz JM. 2017.
449 De novo active sites for resurrected Precambrian enzymes. *Nat Commun* 8:16113.
- 450 20. Clouthier CM, Morin S, Gobeil SMC, Doucet N, Blanchet J, Nguyen E, Gagné SM, Pelletier JN.
451 2012. Chimeric β -Lactamases: Global Conservation of Parental Function and Fast Time-Scale
452 Dynamics with Increased Slow Motions. *PLoS One* 7:e52283.
- 453 21. Gobeil SMC, Clouthier CM, Park J, Gagné D, Berghuis AM, Doucet N, Pelletier JN. 2014.
454 Maintenance of Native-like Protein Dynamics May Not Be Required for Engineering Functional
455 Proteins. *Chem Biol* 21:1330–1340.
- 456 22. González MM, Abriata LA, Tomatis PE, Vila AJ. 2016. Optimization of Conformational
457 Dynamics in an Epistatic Evolutionary Trajectory. *Mol Biol Evol* 33:1768–1776.
- 458 23. Meroueh SO, Fisher JF, Schlegel HB, Mobashery S. 2005. Ab Initio QM/MM Study of Class A
459 β -Lactamase Acylation: Dual Participation of Glu166 and Lys73 in a Concerted Base Promotion
460 of Ser70. *J Am Chem Soc* 127:15397–15407.
- 461 24. Vandavasi VG, Weiss KL, Cooper JB, Erskine PT, Tomanicek SJ, Ostermann A, Schrader TE,
462 Ginell SL, Coates L. 2016. Exploring the Mechanism of β -Lactam Ring Protonation in the Class
463 A β -lactamase Acylation Mechanism Using Neutron and X-ray Crystallography. *J Med Chem*
464 59:474–479.
- 465 25. Drawz SM, Bonomo RA. 2010. Three decades of β -lactamase inhibitors. *Clin Microbiol Rev*
466 23:160–201.
- 467 26. Papp-Wallace KM, Bonomo RA. 2016. New β -lactamase inhibitors in the clinic. *Infect Dis Clin*
468 North Am 30:441–464.
- 469 27. Tehrani KHME, Martin NI. 2018. β -lactam/ β -lactamase inhibitor combinations: an update.

- 470 Medchemcomm 9:1439–1456.
- 471 28. Kurz SG, Bonomo RA. 2012. Reappraising the use of β -lactams to treat tuberculosis. Expert Rev
472 Anti Infect Ther 10:999–1006.
- 473 29. Watkins RR, Papp-Wallace KM, Drawz SM, Bonomo RA. 2013. Novel β -lactamase inhibitors: a
474 therapeutic hope against the scourge of multidrug resistance. Front Microbiol 4:392.
- 475 30. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New β -Lactamase Inhibitors: a Therapeutic
476 Renaissance in an MDR World. Antimicrob Agents Chemother 58:1835–1846.
- 477 31. Elings W, Tassoni R, van der Schoot SA, Luu W, Kynast JP, Dai L, Blok AJ, Timmer M, Florea
478 BI, Pannu NS, Ubbink M. 2017. Phosphate promotes the recovery of *Mycobacterium tuberculosis*
479 β -lactamase from clavulanic acid inhibition. Biochemistry 56:6257–6267.
- 480 32. Soroka D, Ourghanlian C, Compain F, Fichini M, Dubée V, Mainardi JL, Hugonnet JE, Arthur
481 M. 2017. Inhibition of β -lactamases of mycobacteria by avibactam and clavulanate. J Antimicrob
482 Chemother 72:1081–1088.
- 483 33. Ambler RP, Coulson AFW. 1991. A standard numbering scheme for the Class A beta-lactamases.
484 Biochem J 276:269–272.
- 485 34. Pervushin K, Riek R, Wider G, Wüthrich K. 1997. Attenuated T2 relaxation by mutual
486 cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR
487 structures of very large biological macromolecules in solution. Proc Natl Acad Sci U S A
488 94:12366–12371.
- 489 35. Schanda P, Van Melckebeke H, Brutscher B. 2006. Speeding up three-dimensional protein NMR
490 experiments to a few minutes. J Am Chem Soc 128:9042–9043.
- 491 36. Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Llinas M, Ulrich EL, Markley JL,
492 Ionides J, Laue ED. 2005. The CCPN data model for NMR spectroscopy: Development of a
493 software pipeline. Proteins: Struct, Funct, Bioinf 59:687–696.
- 494 37. Bae S-H, Dyson HJ, Wright PE. 2009. Prediction of the rotational tumbling time for proteins with
495 disordered segments. J Am Chem Soc 131:6814–6821.

- 496 38. García de la Torre J, Huertas M., Carrasco B. 2000. HYDRONMR: Prediction of NMR
497 Relaxation of Globular Proteins from Atomic-Level Structures and Hydrodynamic Calculations. *J
498 Magn Reson* 147:138–146.
- 499 39. Bruker Corporation. 2018. Dynamics Center Manual 003:110.
- 500 40. Woessner DE. 1962. Nuclear Spin Relaxation in Ellipsoids Undergoing Rotational Brownian
501 Motion. *J Chem Phys* 37:647–654.
- 502 41. Vallurupalli P, Hansen DF, Stollar E, Meirovitch E, Kay LE. 2007. Measurement of bond vector
503 orientations in invisible excited states of proteins. *Proc Natl Acad Sci U S A* 104:18473–18477.
- 504 42. Delaglio F, Grzesiek S, Vuister G, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: A multidimensional
505 spectral processing system based on UNIX pipes. *J Biomol NMR* 6:277–293.
- 506 43. Hansen DF, Yang D, Feng H, Zhou Z, Wiesner S, Bai Y, Kay LE. 2007. An exchange-free
507 measure of ¹⁵N transverse relaxation: An NMR spectroscopy application to the study of a
508 folding intermediate with pervasive chemical exchange. *J Am Chem Soc* 129:11468–11479.
- 509 44. Hansen DF, Vallurupalli P, Lundström P, Neudecker P, Kay LE. 2008. Probing chemical shifts of
510 invisible states of proteins with relaxation dispersion NMR spectroscopy: How well can we do? *J
511 Am Chem Soc* 130:2667–2675.
- 512 45. Waudby CA, Ramos A, Cabrita LD, Christodoulou J. 2016. Two-Dimensional NMR Lineshape
513 Analysis. *Sci Rep* 6:24826.
- 514 46. Xu H, Hazra S, Blanchard JS. 2012. NXL104 irreversibly inhibits the β-lactamase from
515 *Mycobacterium tuberculosis*. *Biochemistry* 51:4551–4557.
- 516 47. Hugonnet J-E, Blanchard JS. 2007. Irreversible inhibition of the *Mycobacterium tuberculosis*
517 beta-lactamase by clavulanate. *Biochemistry* 46:11998–12004.
- 518 48. Stivers JT, Abeygunawardana C, Mildvan AS, Whitman CP. 1996. ¹⁵N NMR Relaxation
519 Studies of Free and Inhibitor-Bound 4-Oxalocrotonate Tautomerase: Backbone Dynamics and
520 Entropy Changes of an Enzyme upon Inhibitor Binding. *Biochemistry* 35:16036–16047.
- 521 49. Tassoni R, Blok A, Pannu NS, Ubbink M. 2019. New Conformations of Acylation Adducts of

- 522 Inhibitors of β -Lactamase from *Mycobacterium tuberculosis*. *Biochemistry* 58:997–1009.
- 523 50. Lecoq L, Bougault C, Hugonnet JE, Veckerlé C, Pessey O, Arthur M, Simorre JP. 2012.
524 Dynamics induced by β -lactam antibiotics in the active site of *Bacillus subtilis* l,d-transpeptidase.
525 Structure 20:850–861.
- 526 51. Frederick TE, Peng JW. 2018. A gratuitous β -Lactamase inducer uncovers hidden active site
527 dynamics of the *Staphylococcus aureus* BlaR1 sensor domain. *PLoS One* 13:e0197241.
- 528 52. Sagar A, Haleem N, Bashir YM, Ashish. 2017. Search for non-lactam inhibitors of mtb β -
529 lactamase led to its open shape in apo state: new concept for antibiotic design. *Sci Rep* 7:6204.
- 530 53. Olmos JL, Pandey S, Martin-Garcia JM, Calvey G, Katz A, Knoska J, Kupitz C, Hunter MS,
531 Liang M, Oberthuer D, Yefanov O, Wiedorn M, Heyman M, Holl M, Pande K, Barty A, Miller
532 MD, Stern S, Roy-Chowdhury S, Coe J, Nagaratnam N, Zook J, Verburgt J, Norwood T, Poudyal
533 I, Xu D, Koglin J, Seaberg MH, Zhao Y, Bajt S, Grant T, Mariani V, Nelson G, Subramanian G,
534 Bae E, Fromme R, Fung R, Schwander P, Frank M, White TA, Weierstall U, Zatsepin N, Spence
535 J, Fromme P, Chapman HN, Pollack L, Tremblay L, Ourmazd A, Phillips GN, Schmidt M. 2018.
536 Enzyme intermediates captured “on the fly” by mix-and-inject serial crystallography. *BMC Biol*
537 16:59.
- 538 54. Golemi-Kotra D, Meroueh SO, Kim C, Vakulenko SB, Bulychev A, Stemmler AJ, Stemmler TL,
539 Mobashery S. 2004. The importance of a critical protonation state and the fate of the catalytic
540 steps in class A beta-lactamases and penicillin-binding proteins. *J Biol Chem* 279:34665–34673.
- 541 55. Nichols DA, Hargis JC, Sanishvili R, Jaishankar P, Defrees K, Smith EW, Wang KK, Prati F,
542 Renslo AR, Woodcock HL, Chen Y. 2015. Ligand-Induced Proton Transfer and Low-Barrier
543 Hydrogen Bond Revealed by X-ray Crystallography. *J Am Chem Soc* 137:8086–8095.
- 544 56. Pan X, He Y, Lei J, Huang X, Zhao Y. 2017. Crystallographic snapshots of Class A β -lactamase
545 catalysis reveal structural changes that facilitate β -lactam hydrolysis. *J Biol Chem* 4022–4033.
- 546 57. Vandavasi VG, Langan PS, Weiss KL, Parks JM, Cooper JB, Ginell SL, Coates L. 2017. Active-
547 Site Protonation States in an Acyl-Enzyme Intermediate of a Class A β -Lactamase with a

- 548 Monobactam Substrate. *Antimicrob Agents Chemother* 61.
- 549 58. Langan PS, Vandavasi VG, Cooper SJ, Weiss KL, Ginell SL, Parks JM, Coates L. 2018.
550 Substrate Binding Induces Conformational Changes in a Class A β -lactamase That Prime It for
551 Catalysis. *ACS Catal* 8:2428–2437.
- 552 59. Tomanicek SJ, Blakeley MP, Cooper J, Chen Y, Afonine P V., Coates L. 2010. Neutron
553 Diffraction Studies of a Class A β -Lactamase Toho-1 E166A/R274N/R276N Triple Mutant. *J
554 Mol Biol* 396:1070–1080.
- 555 60. Ibuka AS, Ishii Y, Galleni M, Ishiguro M, Yamaguchi K, Frère J-M, Matsuzawa H, Sakai H.
556 2003. Crystal Structure of Extended-Spectrum β -Lactamase Toho-1: Insights into the Molecular
557 Mechanism for Catalytic Reaction and Substrate Specificity Expansion.
- 558 61. Tremblay LW, Hugonnet J-E, Blanchard JS. 2008. Structure of the covalent adduct formed
559 between *Mycobacterium tuberculosis* beta-lactamase and clavulanate. *Biochemistry* 47:5312–
560 5316.

561 **FIGURES**

562 Figure 1. Crystal structure of BlaC (subunit A of PDB entry code 5NJ2).(31) (a) Cartoon representation
563 with indication of α -helices, β -strands and the Ω -loop. Several active site residues are shown in stick
564 representation. (b) Detail of the active site, showing both stick representation and transparent cartoon
565 representation for clarity. Several active site residues and the conserved active site water molecule are
566 indicated.

567

568 Figure 2. Peak intensities. (a) Relative peak intensities of assigned backbone amides in a ^1H , ^{15}N TROSY
569 spectrum, for BlaC in resting state (black squares), bound to clavulanic acid (red circles), and bound to
570 avibactam (blue triangles). The resonance of the C-terminal amide was used for normalization. The
571 break on the horizontal axis represents a BlaC-specific G-G-G-T-loop which is not present in the
572 Ambler numbering. Several active site residues are indicated with grey bars. Secondary structure is

573 indicated above the graph, light and dark grey boxes represent α -helices and β -strands, respectively.
574 Error bars have been omitted for clarity, propagated error from the spectral noise is in all cases <0.03.
575 (b)-(c) Visualization of binding effects on BlaC crystal structure with PDB entry code 5NJ2. Non-
576 proline backbone amides for which no resonance was found in free BlaC are indicated with red spheres.
577 Amides for which the resonance was lost upon inhibitor binding are indicated with orange spheres for
578 clavulanic acid (b) and avibactam (c). Amides for which a resonance could be assigned for resting state
579 as well as bound BlaC are indicated with blue spheres. Proline nitrogen atoms are indicated with black
580 spheres. Amides of several active site residues are indicated for reference.

581

582 Figure 3. CPMG relaxation dispersion data. (a) Contribution of chemical exchange to the R_2 relaxation
583 of backbone ^{15}N resonances in BlaC resting state (black), bound to clavulanic acid (red) and bound to
584 avibactam (blue), as measured by CPMG relaxation dispersion analysis at 20 T. R_{ex} is defined as the
585 $R_{2,\text{eff}}$ at $\nu_{CPMG} = 25 \text{ s}^{-1}$ minus that at 1000 s^{-1} . Error bars represent the 95% confidence interval based on
586 three duplicate delays per experiment. The break on the horizontal axis represents a BlaC-specific G-G-
587 G-T-loop which is not present in the Ambler numbering. Several active site residues are indicated with
588 grey bars. Secondary structure is indicated above the graph; light and dark grey boxes represent α -
589 helices and β -strands, respectively. (b)-(d) Visualization of millisecond dynamics on BlaC structure
590 5NJ2,(31) for BlaC bound to clavulanic acid (b), in free state (c) and bound to avibactam (d). Backbone
591 amides for which $R_{ex} < 3 \text{ s}^{-1}$ are displayed as blue spheres, those with $R_{ex} > 3 \text{ s}^{-1}$ as orange spheres.
592 Residues whose resonances were broadened beyond detection are displayed as red spheres, while those
593 for which R_{ex} could not be determined for another reason (e.g. prolines or too much peak overlap) are
594 displayed as black spheres.

595

596 Figure 4. Example CPMG relaxation dispersion profiles, as measured at 20 T. Data obtained in the free
597 state, bound to clavulanic acid adduct and bound to avibactam are represented in black squares, red

598 circles and blue triangles, respectively. Error bars represent the standard deviation based on three
599 duplicate CPMG frequencies, with a user-defined minimum of 0.8 s^{-1} to avoid overfitting. Lines
600 represent global fits to a two-state exchange model as described in the text.

601

602 Figure 5. Dynamics of BlaC upon reaction with clavulanic acid. Backbone amides for which the
603 resonance has broadened beyond detection are displayed in red, those for which multiple resonances
604 could be assigned in magenta, those for which a transverse relaxation time $T_2 > 60 \text{ ms}$ was found in
605 cyan, those for which the cyan and magenta conditions are both true in orange and those for which no
606 severe dynamics were detected in blue. Proline nitrogen atoms are displayed in black.

607

608 Figure 6. Ω -loop displacement model. Cartoon representation of the BlaC active site in an alignment of
609 BlaC crystal structures in free form (5NJ2 and 5OYO(31)) in green, bound to clavulanic acid adduct
610 (3CG5,(61) 6H2C and 6H2G(49)) in yellow and bound to avibactam (4DF6(46) and 6H2H(49)) in
611 orange. Active site residues Ser70 and Glu166 are shown in stick representation, adducts are omitted for
612 clarity. Structure 6H2H of BlaC bound to avibactam displays a more ‘open’ conformation of the Ω -loop.

613

614 Figure 7. Alternative model involving reorientation of Lys73. BlaC structures observed by Olmos *et al.*,
615 representing bound (PDB 5A92, green carbons) and unbound states (PDB 5A91, yellow carbons), show
616 different orientations for the sidechain of Lys73.(53) Indicated distances are in Ångström.

617













